{"id":4085,"date":"2025-07-11T12:52:23","date_gmt":"2025-07-11T09:52:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4085"},"modified":"2025-07-24T13:36:07","modified_gmt":"2025-07-24T10:36:07","slug":"mutations-amenable-to-exon-50-skipping","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/ru\/mutations-amenable-to-exon-50-skipping\/","title":{"rendered":"\u041c\u0443\u0442\u0430\u0446\u0438\u0438, \u043f\u043e\u0434\u0434\u0430\u044e\u0449\u0438\u0435\u0441\u044f \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043f\u0440\u043e\u043f\u0443\u0441\u043a\u0430 \u044d\u043a\u0437\u043e\u043d\u0430 50 \u043f\u0440\u0438 \u043c\u044b\u0448\u0435\u0447\u043d\u043e\u0439 \u0434\u0438\u0441\u0442\u0440\u043e\u0444\u0438\u0438 \u0414\u044e\u0448\u0435\u043d\u043d\u0430"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration due to mutations in the DMD gene, which encodes the dystrophin protein. Among the innovative treatments under development, exon skipping therapies have shown promise in restoring partial dystrophin function. In particular, exon 50 skipping therapies are designed to treat a subset of mutations and deletions that disrupt the reading frame of the dystrophin gene. <strong>This article explores which mutations and deletions are amenable to exon 50 skipping in DMD and how this therapy works.<\/strong> &#8211; Read More: <a href=\"https:\/\/dmdwarrior.com\/what-is-exon-skipping-and-how-does-it-work\/\">What is Exon Skipping<\/a> &#8211;<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table of Contents<\/h2><nav><ul><li><a href=\"#mutations-amenable-to-exon-50-skipping\">Mutations Amenable to Exon 50 Skipping<\/a><\/li><li><a href=\"#conclusion\">Deletions Amenable for Exon 50 Skipping<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"mutations-amenable-to-exon-50-skipping\">Mutations Amenable to Exon 50 Skipping<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Exon 50 of the dystrophin gene is one of the exons targeted for skipping in exon-skipping therapies. <strong>Mutations amenable to exon 50 skipping is specifically relevant for patients who have deletions in exons 20-49, 22-49, 51, 51-53, 51-55 of the dystrophin gene.<\/strong> These mutations lead to a frameshift, preventing the synthesis of functional dystrophin protein. [<a href=\"https:\/\/dmdwarrior.com\/duchenne-exon-deletion-tool\/\">Discover Our Exon Deletion Search Tool<\/a>]<\/p>\n\n\n\n<div><a href=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-1024x709.jpg\" class=\"td-modal-image\"><figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"709\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-1024x709.jpg\" alt=\"Mutations Amenable to Exon 50 Skipping for Duchenne Muscular Dystrophy patients\" class=\"wp-image-4089\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-1024x709.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-300x208.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-768x532.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-1536x1063.jpg 1536w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-607x420.jpg 607w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-150x104.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-218x150.jpg 218w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-696x482.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping-1068x739.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/07\/Mutations-are-Amenable-to-Exon-50-Skipping.jpg 1890w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><strong><em>Mutations Amenable to Exon 50 Skipping<\/em><\/strong><\/figcaption><\/figure><\/a><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion\">Deletions Amenable for Exon 50 Skipping<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Exon 50 skipping represents a targeted therapeutic strategy for a subset of Duchenne Muscular Dystrophy patients, specifically those with deletions involving exons 20-49, 22-49, 51, 51-53, 51-55.<\/strong> By skipping exon 50, the gene\u2019s reading frame can be restored, allowing the production of a truncated but functional form of dystrophin. This approach holds significant promise for improving the quality of life and slowing disease progression for certain DMD patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite its potential, exon skipping is not a one-size-fits-all solution. Its effectiveness depends on the mutation type and the ability to deliver the therapeutic oligonucleotides to the target tissues. As research progresses and more clinical trials are conducted, exon skipping may become an essential part of the therapeutic arsenal for treating DMD, particularly for patients with mutations amenable to exon 50 skipping.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read More: <a href=\"https:\/\/dmdwarrior.com\/next-generation-exon-skipping-therapies-for-duchenne-muscular-dystrophy\/\">Next Generation Exon Skipping Therapies<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration due to mutations in the DMD gene, which encodes the dystrophin protein. Among the innovative treatments under development, exon skipping therapies have shown promise in restoring partial dystrophin function. In particular, exon 50 skipping therapies are designed to treat a subset [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4091,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[278,279,280,77,178],"class_list":["post-4085","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dmd","tag-exon-50","tag-exon-50-skipping","tag-exon-50-skipping-treatment","tag-exon-skipping","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts\/4085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/comments?post=4085"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts\/4085\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/media\/4091"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/media?parent=4085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/categories?post=4085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/tags?post=4085"}],"curies":[{"name":"WP","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}